Dipyridamole Potentiates Platelet Inhibition by Nitric Oxide

Summary

In a placebo-controlled double blind cross-over experiment the adenosine uptake inhibitor dipyridamole (400 mg/day) did not affect ex vivo platelet aggregation induced by collagen or adenosine-diphosphate (ADP) in an electronic whole blood aggregometer (WBA). Dipyridamole was also inactive in vitro, unless red blood cell injury was deliberately enhanced, thereby increasing the level of free adenine nucleotides. Since dipyridamole also inhibits cyclic guanosine monophosphate (GMP) phosphodiesterase (PDE), we used platelet rich plasma (PRP) to study its interaction with authentic and endothelium-derived nitric oxide (NO). The latter inhibits platelets by increasing cyclic GMP. Dipyridamole (1 to 30 εM), either alone or in combination with a subthreshold concentration of prostacyclin (PGI₂), was inactive. However, when combined with a subthreshold concentration of NO, dipyridamole caused a concentration-dependent platelet suppression, which became more pronounced when PGI₂ was present as well. It is concluded that dipyridamole could reduce the threshold for platelet suppression by NO through inhibition of cyclic GMP PDE.

• References

• 1 Didisheim P. Animal models useful in the study of thrombosis and antithrombotic agents. In: Progress in Hemostasis and Thrombosis.. Spaet TH. (ed) Grune & Stratton, New York and London: 1972. pp 165-97
• 2 FitzGerald GA. Dipyridamole. N Engl J Med 1987; 316: 1247-57
• 3 Gresele P, Zoja C, Deckmyn H, Arnout J, Vermylen J, Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemostas 1983; 50: 852-6
• 4 McElroy FA, Philp RB. Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: possible explanation of mechanism of inhibition of platelet function. Life Sci 1975; 17: 479-93
• 5 Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet JC, Strasbourg FR. Selective inhibition of cyclic nucleotide phosphodiesterase of human, bovine and rat aorta. Biochem Pharmacol 1986; 35: 1743-51
• 6 Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6
• 7 Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9
• 8 Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57: 946-55
• 9 Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181-7
• 10 Busse R. Stimulation of soluble guanylate cyclase activity by endothelium-derived relaxant factor: 3. (Abstr)
• 11 Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-46
• 12 Bult H, Fret HRL, Van den Bossche RM, Herman AG. Platelet inhibition by endothelium-derived relaxing factor from the rabbit perfused aorta. Br J Pharmacol 1988; 95: 1308-14
• 13 Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 1990; 37: 671-81
• 14 Bult H, Fret HRL, Jordaens FH, Herman AG. Anti-aggregating activity of dipyridamole in the presence of nitric oxide and endothelium-derived relaxing factor. J Vascular Med Biol 1989; 1: 79 (Abstr)
• 15 Dudley RA, Edwards P, Ekins RP. et al. Guidelines for immunoassay data processing. Clin Chem 1985; 31: 1264-71
• 16 Rosen JM, Masset H, Delapierre D, Dresse A. Dipyridamole pharmacokinetics in normal volunteers. Arch Int Pharmacodyn 1987; 287: 333-4
• 17 Chevolet C, Van de Velde VJS, Weisenberger H, Herman A, Dresse A. Bioequivalence of two dipyridamole preparations and inhibitory effect on the platelet adenosine uptake in man. Arch Int Pharmacodyn 1981; 253: 321-2
• 18 Kelm M, Feelisch M, Spahr R, Piper H-M, Noack E, Schrader J. Quantitative and kinetic characterization of nitric oxide and EDRF released from cultured endothelial cells. Biochem Biophys Res Commun 1988; 154: 236-44
• 19 Sokal RR, Rohlf FJ. Biometry. The Principles and Practice of Statistics in Biological Research. 2nd edition.. W. H. Freeman and Co., San Francisco, CA: 1981: 859 pp
• 20 Tofler GH, Brezinski D, Schafer AI. et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316: 1514-8
• 21 Meyerson LR, Strano R, Ocheret D. Diurnal concordance of human platelet serotonin content and plasma alpha-1-acid glycoprotein concentration. Pharmacol Biochem Behav 1989; 32: 1043-7
• 22 Guyton AC. Textbook of Medical Physiology. 6th edition.. W. B. Saunders Co, Philadelphia, PA: 1981: 1074 pp
• 23 Galvez A, Badimon L, Badimon J-J, Fuster V. Electrical aggregometry in whole blood from human, pig and rabbit. Thromb Haemostas 1986; 56: 128-32
• 24 Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science 1980; 207: 541-3
• 25 Ingerman-Wojenski CM, Silver MJ. A quick method for screening platelet dysfunctions using the whole blood lumi-aggregometer. Thromb Haemostas 1984; 51: 154-6
• 26 Pengo V, Boschello M, Marzari A, Baca M, Schivazappa L, Dalla Volta S. Adenosine diphosphate (ADP)-induced alpha-granules release from platelets of native whole blood is reduced by ticlopidine but not by aspirin or dipyridamole. Thromb Haemostas 1986; 56: 147-50
• 27 Heptinstall S, Fox S, Crawford J, Hawkins M. Inhibition of platelet aggregation in whole blood by dipyridamole and aspirin. Thromb Res 1986; 42: 215-23
• 28 Edlund A, Siden A, Sollevi A. Evidence for an anti-aggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole. Thromb Res 1987; 45: 183-90
• 29 Saniabadi AR, Lowe GDO, Barbenel JC, Forbes CD. Effect of dipyridamole on spontaneous platelet aggregation in whole blood decreases with the time after venepuncture: evidence for the role of ADP. Thromb Haemostas 1987; 58: 744-8
• 30 Manderson JA, Cocks TM, Campbell GR. Balloon catheter injury to rabbit carotid artery. II. Selective increase in reactivity to some vasoconstrictor drugs. Atherosclerosis 1989; 9: 299-307
• 31 Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemostas 1986; 55: 12-8
• 32 Martin W, Smith JA, White DG. The mechanism by which haemoglobin inhibits the relaxation of rabbit aorta induced by nitrovasodilators, nitric oxide, or bovine retractor penis inhibitory factor. Br J Pharmacol 1986; 89: 563-71
• 33 Busse R, Luckhoff A, Bassenge E. Endothelium-derived relaxant factor inhibits platelet activation. Naunyn-Schmiedebergs Arch Pharmacol 1987; 336: 566-71
• 34 Furlong B, Henderson AH, Lewis MJ, Smith JA. Endotheliumderived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol 1987; 90: 687-92
• 35 Bult H, Fret HRL, Jordaens FH, Herman AG. Dipyridamole potentiates the anti-aggregating and vasodilator activity of nitric oxide. Eur J Pharmacol 1991 (in press)
• 36 Tangelder GJ, Slaaf DW, Muijtjens AMM, Arts T, Oude Egbrink MGA, Reneman RS. Velocity profiles of blood platelets and red blood cells flowing in arterioles of the rabbit mesentery. Circ Res 1986; 59: 505-14
• 37 Fuster V, Adams PC, Badimon JJ, Chesebro JH. Platelet-inhibitor drugs' role in coronary artery disease. Progr Cardiovasc Dis 1987; 5: 325-46
• 38 Groves HL, Kinlough-Rathbone RL, Mustard JF. Development of nonthrombogenicity of injured rabbit aortas despite inhibition of platelet adherence. Arteriosclerosis 1986; 6: 189-95